Open AccessAn audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients
Author(s) -
Patil Vm,
Santam Chakraborty,
Jithin Tk,
Sajith Babu Tp,
S Babu,
Suman Kumar,
Biji Ms,
Atanu Bhattacharjee,
Satheesan Balasubramanian
Publication year - 2016
Publication title -
south asian journal of cancer
Language(s) - English
Resource type - Journals
eISSN - 2278-4306
pISSN - 2278-330X
DOI - 10.4103/2278-330x.181624
Subject(s) - medicine , erlotinib , head and neck cancer , cetuximab , chemotherapy , regimen , oncology , performance status , chemotherapy regimen , progressive disease , surgery , cancer , colorectal cancer , epidermal growth factor receptor
Addition of erlotinib to metronomic chemotherapy (MCT) may lead to further improvement in progression-free survival (PFS) and overall survival in head and neck cancers. The aim of this study was to study the PFS with MCT + erlotinib combination in our setting.